Middle East & Africa Transdermal Drug Delivery System Market Forecast to 2030

Middle East & Africa Transdermal Drug Delivery System Market Forecast to 2030 – Regional Analysis – by Type (Transdermal Patches, Transdermal Gel, Transdermal Sprays, and Others), Application (Cardiovascular Diseases, Central Nervous System Disorders, Pain Management, Hormonal Applications, and Other Applications), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Send Enquiry

$2,840$4,440

Description

The Middle East & Africa transdermal drug delivery system market is expected to grow from US$ 1,147.56 million in 2022 to US$ 1,525.09 million by 2030. It is estimated to register a CAGR of 3.6% from 2022 to 2030.

Increasing Prevalence of Chronic Diseases Bolsters Middle East & Africa Transdermal Drug Delivery System Market

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer’s disease or mild-to-moderate dementia associated with Parkinson’s disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.

Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.

Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer’s disease, and diabetes bolster the growth of the transdermal drug delivery system market.

Middle East & Africa Transdermal Drug Delivery System Market Overview

The transdermal drug delivery system market in the MEA is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of MEA. The market growth is expected to grow due to the high prevalence of chronic diseases, increasing healthcare expenditure, and rising R&D activities across the region. Moreover, the rising demand for technologically advanced medical devices helps propel the market growth during the forecast period. According to a study “Noncommunicable diseases and health system responses in Saudi Arabia: focus on policies and strategies. A qualitative study,” published by Health Research Policy and Systems in 2022, noncommunicable diseases (NCDs), particularly diabetes, CVD, and other chronic diseases, are responsible for an increasing disease and economic burden in Saudi Arabia. According to Saudi Health Ministry statistics, cardiovascular diseases account for 37% of all deaths in Saudi Arabia. According to the United Nations Population Fund (UNFPA), Saudi Arabia is expected to experience a five-fold rise in the aging population from 2 million (5.9%) in 2020 to 10.5 million by 2050 (23.7%). The geriatric population is prone to health conditions such as cardiovascular diseases, lung infections, and diabetes. According to Global Burden of Disease data published in 2020, Saudi Arabia has a high prevalence of noncommunicable diseases such as stroke, heart disease, kidney disease, COPD, and diabetes. Furthermore, deaths related to diabetes increased by ~79%, chronic kidney disease by 41.2%, and stroke by 27.6% between 2009 and 2019. Thus, the high prevalence of mentioned diseases fuels the demand for transdermal drug delivery systems, thereby boosting the market growth.

Saudi Arabia partnered with the UK academic and research institutions in 2019 for a US$1.6 billion initiative to enhance the Kingdom’s domestic research and development capabilities. In Saudi Arabia, due to the increasing demand for healthcare services, the rising government initiatives favor increased participation from the private sector for their expansion. Thus, the rising prevalence of cardiovascular diseases in the population and the rise in healthcare expenditure in Saudi Arabia play a vital role in the growth of the transdermal drug delivery system market.

Middle East & Africa Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Transdermal Drug Delivery System Market Segmentation

The Middle East & Africa transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the Middle East & Africa transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the Middle East & Africa transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Middle East & Africa transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the Middle East & Africa transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Middle East & Africa transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the Middle East & Africa transdermal drug delivery system market in 2022.

Based on country, the Middle East & Africa transdermal drug delivery system market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Novartis AG, and Viatris Inc are some of the leading companies operating in the Middle East & Africa transdermal drug delivery system market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

,

Year of Publication:

At 3.6% CAGR, Middle East & Africa Transdermal Drug Delivery System Market is Speculated to be Worth US$ 1,525.09 million by 2030, says the Research Team

According to the Research Team’ research, the Middle East & Africa transdermal drug delivery system market was valued at US$ 1,147.56 million in 2022 and is expected to reach US$ 1,525.09 million by 2030, registering a CAGR of 3.6% from 2022 to 2030. Increasing prevalence of chronic diseases and advancements in smart patches and 3D-printed patches are among the critical factors attributed to the Middle East & Africa transdermal drug delivery system market expansion.

A transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being conducted in this field and the increasing interest of researchers in this form of drug delivery, a large number of transdermal patches are likely to reach the marketplace in the future. Transdermal patches are used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various medical conditions. Recently, these patches have been explored to deliver biologics in various applications. Smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a lead scientist at Swansea University developed a new smart patch to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson’s and Alzheimer’s using the microneedle technology. These smart patches comprise numerous microneedles designed to penetrate the skin barrier in a minimally invasive manner, followed by monitoring the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or at home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.

According to an article titled “3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery,” published in the National Library of Medicine in November 2021, personalized 3D-printed patches that conform to the skin surface can be used for acetyl-hexapeptide 3 (AHP-3) delivery. In this study, two liquid monomers-polyethylene glycol diacrylate (PEGDA) and vinylpyrrolidone (VP)-were used in different proportions to improve the mechanical strength, polymerization rate, and swelling rate of the final polymer. Optimal drug loading on the resin indicated that AHP-3 remained stable throughout the manufacturing process and had no effect on the physical properties of the final polymer. Using a 3D scanned facial model, a personalized patch was designed in computer-aided design software, and it was fabricated in optimized resin using a digital light processing 3D printer. The in-vitro characterization of prepared transdermal patches has shown their ability to penetrate human cadaver skin, further remaining intact upon compression. “3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery” is the first study demonstrating personalized patches made using photopolymers, and it has introduced a novel approach to improve the transdermal delivery of drugs for effective wrinkle management.

Thus, the adoption of 3D printing technology and smart patches is likely to offer opportunities to the transdermal drug delivery systems market in the coming years.

On the contrary, adverse effects and recall of transdermal drug delivery systems hamper the growth of Middle East & Africa transdermal drug delivery system market.

Based on type, the Middle East & Africa transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held 39.9% share of Middle East & Africa transdermal drug delivery system market in 2022, amassing US$ 457.96 million. It is projected to garner US$ 620.51 million by 2030 to expand at 3.9% CAGR during 2022-2030. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Middle East & Africa transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held 40.8% share of Middle East & Africa transdermal drug delivery system market in 2022, amassing US$ 468.24 million. It is projected to garner US$ 621.64 million by 2030 to expand at 3.6% CAGR during 2022-2030. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Middle East & Africa transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held 43.1% share of Middle East & Africa transdermal drug delivery system market in 2022, amassing US$ 494.68 million. It is projected to garner US$ 656.93 million by 2030 to expand at 3.6% CAGR during 2022-2030.

Based on country, the Middle East & Africa transdermal drug delivery system market has been categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 32.8% share of Middle East & Africa transdermal drug delivery system market in 2022. It was assessed at US$ 376.84 million in 2022 and is likely to hit US$ 522.82 million by 2030, exhibiting a CAGR of 4.2% during 2022-2030.

Key players operating in the Middle East & Africa transdermal drug delivery system market are Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Novartis AG, and Viatris Inc, among others.

In October 2023, Novartis completed the Spin-off of Sandoz, its Generics and Biosimilars business. Novartis executed separation of the Sandoz business to create an independent company by way of a 100% Spin-off.

In August 2023, Novartis acquired Chinook Therapeutics Inc. Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront. The deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A receptor antagonist, and zigakibart, an anti-APRIL monoclonal antibody.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa Transdermal Drug Delivery System Market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa Transdermal Drug Delivery System Market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Transdermal Drug Delivery System Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Increasing Prevalence of Chronic Diseases
4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis
5. Transdermal Drug Delivery System Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 – 2030
6. Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
6.3.1 Overview
6.3.2 Transdermal Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Drug-in-Adhesive Patches
6.3.2.1.1 Overview
6.3.2.1.2 Drug-in-Adhesive Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Matrix Patches
6.3.2.2.1 Overview
6.3.2.2.2 Matrix Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.3 Reservoir Membrane Patches
6.3.2.3.1 Overview
6.3.2.3.2 Reservoir Membrane Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.4 Vapor Patches
6.3.2.4.1 Overview
6.3.2.4.2 Vapor Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
6.4.1 Overview
6.4.2 Transdermal Gels: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
6.5.1 Overview
6.5.2 Transdermal Sprays: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Others
6.6.1 Overview
6.6.2 Others: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
7.3.1 Overview
7.3.2 Cardiovascular Diseases: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
7.4.1 Overview
7.4.2 Central Nervous System Disorders: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
7.5.1 Overview
7.5.2 Pain Management: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.1 Opioid
7.5.2.1.1 Overview
7.5.2.1.2 Opioid: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.2 Non-Opioid
7.5.2.2.1 Overview
7.5.2.2.2 Non-Opioid: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
7.6.1 Overview
7.6.2 Hormonal Applications: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.1 Transdermal Estrogen & Progesterone Therapy
7.6.2.1.1 Overview
7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.2 Testosterone Replacement
7.6.2.2.1 Overview
7.6.2.2.2 Testosterone Replacement: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
7.7.1 Overview
7.7.2 Other Application: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – Country Analysis
9.1 Middle East & Africa Transdermal Drug Delivery System Market
9.1.1 Middle East & Africa Transdermal Drug Delivery System Market, by Country
9.1.1.1 South Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 South Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.1.3.1 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.1.4 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.1.4.1 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.1.4.2 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.1.5 South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.2.4 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.2.4.1 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.2.4.2 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.2.5 Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 UAE: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 UAE: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.3.4 UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.3.4.1 UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.3.4.2 UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.3.5 UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.4 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Overview
9.1.1.4.2 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.3 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.4.3.1 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.4.4 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.4.4.1 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.4.4.2 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.4.5 Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Transdermal Drug Delivery System Market Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Johnson & Johnson
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Viatris Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. Middle East & Africa Transdermal Drug Delivery System Market Segmentation
Table 2. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 7. South Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 10. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 11. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 12. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 13. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 15. UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 18. UAE: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 19. UAE: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 20. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 26. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
Table 27. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
Table 28. Glossary of Terms, Middle East & Africa Transdermal Drug Delivery System Market

LIST OF FIGURES

Figure 1. Middle East & Africa Transdermal Drug Delivery System Market Segmentation, By Country
Figure 2. Middle East & Africa Transdermal Drug Delivery System Market: Key Industry Dynamics
Figure 3. Middle East & Africa Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Transdermal Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Drug-in-Adhesive Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Matrix Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Reservoir Membrane Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Vapor Patches: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Transdermal Gels: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Transdermal Sprays: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
Figure 15. Cardiovascular Diseases: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Central Nervous System Disorders: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Pain Management: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Opioid: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Non-Opioid: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Hormonal Applications: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Transdermal Estrogen & Progesterone Therapy: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Testosterone Replacement: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Other Application: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Middle East & Africa Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 25. Hospital Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Middle East & Africa Transdermal Drug Delivery System Market, by Key Country – Revenue (2022) (US$ Million)
Figure 30. Middle East & Africa Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
Figure 31. South Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Saudi Arabia: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. UAE: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Rest of Middle East & Africa: Middle East & Africa Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Growth Strategies in the Transdermal Drug Delivery System Market

1. Boehringer Ingelheim International GmbH
2. GSK Plc
3. Hisamitsu Pharmaceutical Co Inc
4. Johnson & Johnson
5. Novartis AG
6. Viatris Inc

Reviews

There are no reviews yet.

Be the first to review “Middle East & Africa Transdermal Drug Delivery System Market Forecast to 2030”